SMCypI C31 

SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction^[1][2].

IC50: 0.1 µM (Peptidyl-prolyl cis/trans isomerases (PPIase))^[2]

SMCypI C31 (C31) inhibited the replication of genotype 1a, 1b, 2a, 3a, and 5a HCV-SGRs and chimeric genotype 2a/4a HCV-SGRs, with EC₅₀ values of 3.80 µM, 2.95 µM, 2.30 µM, 7.76 µM, 1.20 µM and 1.40 µM, respectively^[1].
SMCypI C31 also inhibits the replication of the infectious J6/JFH1 virus, with an EC₅₀ of 2.80 μM. SMCypI C31 inhibits DBN-3acc RNA replication in a dose-dependent manner, with a maximal 244-fold HCV RNA reduction at 10 μM^[1].
SMCypI C31 (C31) inhibits the replication of other members of the Flaviviridae family. SMCypI C31 inhibits viral replication of DENV (EC₅₀ of 7.3 μM), YFV (EC₅₀ of 27.2 μM), and ZIKV (EC₅₀ of 48.0 μM)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

474.62

C₂₇H₃₀N₄O₂S

2649904-85-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Quentin Nevers, et al. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00126-18.  [Content Brief]

  [2]. Abdelhakim Ahmed-Belkacem, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016 Sep 22;7:12777.  [Content Brief]